(S)-Pralatrexate
(S)-Pralatrexate is an orally active anticancer compound. (S)-Pralatrexate exhibits cytotoxic activity against cancer cells and possesses anti-inflammatory activity. (S)-Pralatrexate can be used in research related to prostate cancer, breast cancer, rheumatoid arthritis, etc.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1320211-69-5
- Formule: C23H23N7O5
- Masse moléculaire:477.48
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| SK-BR-3 | IC50 |
11.9 nM
|
Inhibition of cell growth against human SKBR-3 breast cancer cells assessed via MTS assay, following 3-hour treatment with (S)-Pralatrexate and additional 72-hour incubation in growth medium.
Inhibition of cell growth against human SKBR-3 breast cancer cells assessed via MTS assay, following 3-hour treatment with (S)-Pralatrexate and additional 72-hour incubation in growth medium.
|
US20110190305A1 |
| MDA-MB-435 | IC50 |
100 nM
|
Inhibition of cell growth against human MDA-MB-435 melanoma cells assessed via MTS assay, following 3-hour treatment with (S)-Pralatrexate and additional 72-hour incubation in growth medium.
Inhibition of cell growth against human MDA-MB-435 melanoma cells assessed via MTS assay, following 3-hour treatment with (S)-Pralatrexate and additional 72-hour incubation in growth medium.
|
US20110190305A1 |
| NCI-H460 | IC50 |
289 nM
|
Inhibition of cell growth against human NCI-H460 lung cancer cells assessed via MTS assay, following 3-hour treatment with (S)-Pralatrexate and additional 72-hour incubation in growth medium (first assay).
Inhibition of cell growth against human NCI-H460 lung cancer cells assessed via MTS assay, following 3-hour treatment with (S)-Pralatrexate and additional 72-hour incubation in growth medium (first assay).
|
US20110190305A1 |
| NCI-H460 | IC50 |
169.3 nM
|
Inhibition of cell growth against human NCI-H460 lung cancer cells assessed via MTS assay, following 3-hour treatment with (S)-Pralatrexate and additional 72-hour incubation in growth medium (repeat assay).
Inhibition of cell growth against human NCI-H460 lung cancer cells assessed via MTS assay, following 3-hour treatment with (S)-Pralatrexate and additional 72-hour incubation in growth medium (repeat assay).
|
US20110190305A1 |
| CWR22R | IC50 |
13.3 nM
|
Inhibition of cell growth against human CWR22-RV1 prostate cancer cells assessed via MTS assay, following 3-hour treatment with (S)-Pralatrexate and additional 72-hour incubation in growth medium.
Inhibition of cell growth against human CWR22-RV1 prostate cancer cells assessed via MTS assay, following 3-hour treatment with (S)-Pralatrexate and additional 72-hour incubation in growth medium.
|
US20110190305A1 |
In Vitro
(S)-Pralatrexate (PDX-10a) (3 pM-10 μM; 3 h) potently inhibits growth of SKBR-3 human breast cancer cells (IC50 = 11.9 nM), MDA-MB-435 human melanoma cells (IC50 = 100 nM), NCI-H460 human lung cancer cells (IC50 = 289 nM, 169.3 nM), and CWR22-RV1 human prostate cancer cells (IC50 = 13.3 nM) in a dose-dependent manner in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SKBR-3 human breast cancer cells, MDA-MB-435 human melanoma cells, NCI-H460 human lung cancer cells, CWR22-RV1 human prostate cancer cells
-
Concentration:3 pM-10 μM
-
Incubation Time:3 h
-
Result:Inhibited cell growth in SKBR-3 breast cancer cells with an IC50 of 11.9 nM.
Inhibited cell growth in MDA-MB-435 melanoma cells with an IC50 of 100 nM.
Inhibited cell growth in NCI-H460 lung cancer cells with an IC50 of 289 nM in the first assay and 169 nM in the repeat assay.
Inhibited cell growth in CWR22-RV1 prostate cancer cells with an IC50 of 13.3 nM.
Exhibited dose-dependent responses across all cell lines.
In Vivo
(S)-Pralatrexate exhibits enhanced prophylactic antiarthritic efficacy relative to racemic PDX and/or PDX-10b in a Type II collagen-induced rheumatoid arthritis model in DBA/1 mice[1].
(S)-Pralatrexate (0.025-0.075 mg/kg; p.o.; daily; 17 days) exhibits enhanced antiarthritic efficacy relative to racemic PDX and/or PDX-10b in a type II collagen-induced rheumatoid arthritis model in female Lewis rats[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female Lewis rats[1]
-
Dosage:0.025 mg/kg; 0.05 mg/kg; 0.075 mg/kg
-
Administration:p.o.; daily; 17 days
-
Result:Showed increased antiarthritic activity relative to racemic PDX and/or PDX-10b for some aspects of arthritis (reduced ankle diameter AUC, reduced final paw weight).
Chemical Information
-
CAS No. 1320211-69-5
-
Masse moléculaire 477.48
-
Formule C23H23N7O5
-
SMILES
NC=1C2=C(N=CC(C[C@H](CC#C)C3=CC=C(C(N[C@@H](CCC(O)=O)C(O)=O)=O)C=C3)=N2)N=C(N)N1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Cotton Pellet Granuloma
Cotton pellet granuloma is a classical in vivo chronic inflammation model used to evaluate the anti-inflammatory potential of test substances by measuring their ability to inhibit granuloma tissue formation around an implanted foreign body (cotton pellet) in rodents. The method is based on the biological response to a sterile implanted material, which induces proliferative phase inflammation characterized by fibroblast proliferation and collagen-rich granuloma formation, and the final readout reflects the extent of chronic inflammatory tissue growth surrounding the pellet. In multiple preclinical pharmacological evaluations, inhibition of cotton pellet-induced granuloma formation has been used as an indicator of anti-inflammatory activity in both synthetic and natural product screening contexts.
-
Carrageenan-Induced Paw Edema
Carrageenan-induced paw edema is an acute inflammation model in which intraplantar injection of carrageenan induces localized inflammatory swelling characterized by vascular permeability, leukocyte infiltration, and production of inflammatory mediators such as prostaglandins and cytokines, making it widely used to evaluate anti-inflammatory agents in vivo. The resulting paw volume or thickness increase is quantified over time as a direct readout of inflammatory intensity and drug efficacy, typically reflecting cyclooxygenase-mediated prostaglandin-driven edema formation and immune cell recruitment in peripheral tissue[20].
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)